Showing results (131-140 of 163) with videos related to

Sort By:
Pageof 17
Blood|March 16, 2018
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLLMichael Hallek, Bruce D Cheson, Daniel Catovsky, et al.
Haematologica|January 19, 2011
The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issuesRichard A Van Etten, Steffen Koschmieder, Francois Delhommeau, et al.
Blood|February 6, 2013
Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategiesPratap Neelakantan, Gareth Gerrard, Claire Lucas, et al.
Frontiers in Cellular and Infection Microbiology|August 6, 2021
A Metatranscriptomics Survey of Microbial Diversity on Surfaces Post-Intervention of cleanSURFACES® Technology in an Intensive Care UnitJeremy Chen See, Truc Ly, Alexander Shope, et al.
British Journal of Haematology|September 4, 2010
A European consensus report on blood cell identification: terminology utilized and morphological diagnosis concordance among 28 experts from 17 countries within the European LeukemiaNet network WP10, on behalf of the ELN Morphology FacultyGina Zini, Barbara Bain, Peter Bettelheim, et al.
Blood|August 10, 2007
A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemiaGabrielle S Sellick, Lynn R Goldin, Ruth W Wild, et al.
Cell Reports|August 16, 2016
Genetic Predisposition to Chronic Lymphocytic Leukemia Is Mediated by a BMF Super-Enhancer PolymorphismRadhika Kandaswamy, Georgina P Sava, Helen E Speedy, et al.
Nature Communications|August 11, 2019
Insight into genetic predisposition to chronic lymphocytic leukemia from integrative epigenomicsHelen E Speedy, Renée Beekman, Vicente Chapaprieta, et al.
American Journal of Hematology|January 11, 2012
BCR-ABL1 kinase domain mutations: methodology and clinical evaluationMary Alikian, Gareth Gerrard, Papagudi G Subramanian, et al.
Haematologica|April 21, 2009
The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinibJamshid Sorouri Khorashad, Simon Wagner, Liat Greener, et al.
Pageof 17